[go: up one dir, main page]

HUP0004935A3 - Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists - Google Patents

Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists

Info

Publication number
HUP0004935A3
HUP0004935A3 HU0004935A HUP0004935A HUP0004935A3 HU P0004935 A3 HUP0004935 A3 HU P0004935A3 HU 0004935 A HU0004935 A HU 0004935A HU P0004935 A HUP0004935 A HU P0004935A HU P0004935 A3 HUP0004935 A3 HU P0004935A3
Authority
HU
Hungary
Prior art keywords
production
carboxylic acid
acid derivatives
receptor antagonists
novel carboxylic
Prior art date
Application number
HU0004935A
Other languages
Hungarian (hu)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19738578A external-priority patent/DE19738578A1/en
Priority claimed from DE1998111915 external-priority patent/DE19811915A1/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of HUP0004935A2 publication Critical patent/HUP0004935A2/en
Publication of HUP0004935A3 publication Critical patent/HUP0004935A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU0004935A 1997-09-04 1998-08-24 Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists HUP0004935A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19738578A DE19738578A1 (en) 1997-09-04 1997-09-04 Carboxylic acid derivatives useful as endothelin A and B antagonists also active as renin and angiotensin inhibitors
DE1998111915 DE19811915A1 (en) 1998-03-18 1998-03-18 New carboxylic acid derivatives
PCT/EP1998/005354 WO1999011629A1 (en) 1997-09-04 1998-08-24 Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists

Publications (2)

Publication Number Publication Date
HUP0004935A2 HUP0004935A2 (en) 2001-10-28
HUP0004935A3 true HUP0004935A3 (en) 2001-12-28

Family

ID=26039663

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004935A HUP0004935A3 (en) 1997-09-04 1998-08-24 Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists

Country Status (21)

Country Link
EP (1) EP1009741A1 (en)
JP (1) JP2001514254A (en)
KR (1) KR20010023615A (en)
CN (1) CN1269792A (en)
AR (1) AR017052A1 (en)
AU (1) AU748610B2 (en)
BG (1) BG104222A (en)
BR (1) BR9811631A (en)
CA (1) CA2302350A1 (en)
CO (1) CO4970738A1 (en)
HR (1) HRP980484A2 (en)
HU (1) HUP0004935A3 (en)
ID (1) ID25620A (en)
IL (1) IL134276A0 (en)
NO (1) NO20001077L (en)
NZ (1) NZ502660A (en)
PL (1) PL338954A1 (en)
SK (1) SK1522000A3 (en)
TR (1) TR200000602T2 (en)
TW (1) TW546295B (en)
WO (1) WO1999011629A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19924892A1 (en) * 1999-06-01 2000-12-07 Basf Ag New carboxylic acid derivatives with aryl-substituted nitrogen heterocycles, their production and use as endothelin receptor antagonists
JP2009538862A (en) * 2006-05-29 2009-11-12 ニコックス エス エイ Nitroheterocyclic compounds as endothelin receptor antagonists
AU2009221179A1 (en) 2008-03-05 2009-09-11 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
US8962832B2 (en) * 2009-07-10 2015-02-24 Cadila Healthcare Limited Process for the preparation of ambrisentan and novel intermediates thereof
JP5780528B2 (en) 2010-02-19 2015-09-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tricyclic pyridine derivatives, medicaments containing such compounds, their use and methods for their preparation
WO2013024130A1 (en) 2011-08-17 2013-02-21 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411225A1 (en) * 1994-03-31 1995-10-05 Basf Ag Use of carboxylic acid derivatives as a drug
DE19533023B4 (en) * 1994-10-14 2007-05-16 Basf Ag New carboxylic acid derivatives, their preparation and use
US6136828A (en) * 1996-02-01 2000-10-24 Smithkline Beecham Corporation Endothelin receptor antagonists
DE19614542A1 (en) * 1996-04-12 1997-10-16 Basf Ag New carboxylic acid derivatives, their production and use
DE19636046A1 (en) * 1996-09-05 1998-03-12 Basf Ag New carboxylic acid derivatives, their production and use as mixed ET¶A¶ / ET¶B¶ receptor antagonists

Also Published As

Publication number Publication date
SK1522000A3 (en) 2000-08-14
HRP980484A2 (en) 1999-06-30
NO20001077D0 (en) 2000-03-02
CN1269792A (en) 2000-10-11
KR20010023615A (en) 2001-03-26
EP1009741A1 (en) 2000-06-21
HUP0004935A2 (en) 2001-10-28
PL338954A1 (en) 2000-12-04
CA2302350A1 (en) 1999-03-11
JP2001514254A (en) 2001-09-11
BG104222A (en) 2001-02-28
NO20001077L (en) 2000-03-02
ID25620A (en) 2000-10-19
AU9533398A (en) 1999-03-22
AR017052A1 (en) 2001-08-22
NZ502660A (en) 2002-02-01
TR200000602T2 (en) 2000-12-21
WO1999011629A1 (en) 1999-03-11
AU748610B2 (en) 2002-06-06
IL134276A0 (en) 2001-04-30
CO4970738A1 (en) 2000-11-07
TW546295B (en) 2003-08-11
BR9811631A (en) 2000-09-26

Similar Documents

Publication Publication Date Title
AU4552497A (en) Novel carboxylic acid derivatives, their preparation and use as mixed eta/etb receptor antagonists
HUP0000942A3 (en) Quinoline and quinazoline compounds pharmaceutical compositions containing them, process producing them and their use
HUP9901312A3 (en) Novel alfa-hydroxylic acid derivatives, their production and use
HRP970199A2 (en) New carboxylic acid derivatives, their production and use
IL135347A0 (en) New carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists
HRP970200A2 (en) Novel carboxylic acid derivatives, their production and use
IL134572A (en) Substituted 1,2,3,4,5,6-hexahydro-2, 6-methano-3-benzazocin - 10 -ols, methods for their production and use thereof as medicaments
IL134276A0 (en) Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists
AU4991797A (en) Piperazino derivatives as neurokinin antagonists
IL130251A0 (en) Heterocyclic carboxylic acid derivatives the production and use thereof as endothelin receptor antagonists
BG104022A (en) New beta-amino and beta-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists
NZ315846A (en) Endothelin receptor antagonists, in particular, substituted pyrazol-4-yl-substituted-prop-2-enoic acid derivatives
PL348667A1 (en) Pyrrolidine carboxylic acid derivatives as endothelin antagonists
IL137038A0 (en) 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists
ZA988053B (en) Novel carboxylic acid derivatives, their preparation and use as mixed ETA/ETB receptor antagonists.
AU2624799A (en) Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed etA/etB-receptor antagonists
IL135461A0 (en) NOVEL HETEROCYCLICALLY SUBSTITUTED α- HYDROXYCARBOXLIC ACID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS
IL147666A0 (en) Novel carboxylic acid derivatives with 5, 6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists
AU3036400A (en) New beta-amide and beta-sulfonamide carboxylic acid derivatives, their preparation and their use as endothelin receptor antagonists
AU2101399A (en) Piperazino derivatives as neurokinin antagonists
IL140915A0 (en) New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists
IL132615A0 (en) Pyrrolidine carboxylic acid derivatives as endothelin antagonists
HK1047102A1 (en) Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists
WO1998052912A3 (en) Leukotriene b4 antagonists, in particular 3-carba-tetrahydronaphthalene-ltb4 antagonists
ZA971467B (en) Piperazino derivatives as neurokinin antagonists.